Relaxation of the criteria for entry to the UK Clozapine Central Non-Rechallenge Database: a modelling study

Journal article


Ebenezer Oloyede, Eromona Whiskey, Cecilia Casetta, Olubanke Dzahini, Danielle Dunnett, Shreyans Gandhi, Prof Fiona Gaughran, Prof Sukhi Shergill, Prof Philip McGuire, Prof James H MacCabe and Prof David Taylor 2022. Relaxation of the criteria for entry to the UK Clozapine Central Non-Rechallenge Database: a modelling study. The Lancet: Psychiatry. 9 (8), pp. 636-644. https://doi.org/10.1016/S2215-0366(22)00188-2
AuthorsEbenezer Oloyede, Eromona Whiskey, Cecilia Casetta, Olubanke Dzahini, Danielle Dunnett, Shreyans Gandhi, Prof Fiona Gaughran, Prof Sukhi Shergill, Prof Philip McGuire, Prof James H MacCabe and Prof David Taylor
Abstract

Background
Clozapine is uniquely effective in treatment-resistant psychosis. In the UK, patients must discontinue clozapine indefinitely if they are placed on the Central Non-Rechallenge Database (CNRD) after their haematological parameters fall below particular thresholds. Under exceptional circumstances, patients can be rechallenged on clozapine under an off-licence agreement. In the USA in 2015, restrictive practice was discontinued to allow greater flexibility for clozapine maintenance. The absolute neutrophil count leading to treatment interruption was lowered from less than 1·5 × 109/L to less than 1·0 × 109/L and platelet and white cell count monitoring were ceased. We aimed to investigate the implications of a similar policy change on clozapine use in the UK.

Methods
This was a modelling study of all patients registered on the UK CNRD. First, we determined the proportion of patients placed on the database in the UK who would have had to discontinue clozapine treatment under the US Food and Drug Administration (FDA) criteria. Second, we compared the haematological characteristics of patients who did or did not meet FDA criteria for discontinuing clozapine, including the time to registration from clozapine initiation and the proportion of cases of severe neutropenia at registration. Third, we investigated the success rates of clozapine re-challenge for patients that had been placed on the CNRD. Successful rechallenge was defined as no recurrence of CNRD registration.

Findings
Between May 2, 2002 and March 1, 2021, 3731 patients were placed on the CNRD, with a mean age of 47 years (SD 15), including 1420 (38%) women and 2311 (62%) men, of whom 3089 (83%) were White, 360 (10%) were Black, 190 (5%) were Asian, and 92 (2%) were classified as other. 566 (15%) of 3731 patients met the equivalent criteria for clozapine discontinuation under the FDA guidelines. The median time to CNRD registration from clozapine initiation was 1·6 years (IQR 0·2–4·9). Data for 519 rechallenged patients were examined; 419 (81%) were successful. Clozapine rechallenge success rates were broadly similar between individuals who did not meet the US CNRD registration criteria (36 [78%] of 46) and those who did meet the criteria (383 [81%] of 473).

Interpretation
Implementing the revised FDA monitoring criteria in the UK would substantially reduce clozapine discontinuation for haematological reasons, which would greatly improve the mental health outcomes of these patients without having a major effect on their physical health.

KeywordsUK Clozapine Central Non-Rechallenge Database
Year2022
JournalThe Lancet: Psychiatry
Journal citation9 (8), pp. 636-644
PublisherElsevier
ISSN2215-0366
2215-0374
Digital Object Identifier (DOI)https://doi.org/10.1016/S2215-0366(22)00188-2
Official URLhttps://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(22)00188-2
Publication dates
Online14 Jul 2022
Publication process dates
Deposited19 May 2023
Accepted author manuscript
License
Output statusPublished
Permalink -

https://repository.canterbury.ac.uk/item/949zy/relaxation-of-the-criteria-for-entry-to-the-uk-clozapine-central-non-rechallenge-database-a-modelling-study

Download files


Accepted author manuscript
CNRD_Manuscript.pdf
License: CC BY-NC-ND 4.0

  • 0
    total views
  • 7
    total downloads
  • 0
    views this month
  • 7
    downloads this month

Export as

Related outputs

Do loneliness and social exclusion breed paranoia? An experience sampling investigation across the psychosis continuum.
Bell, Victoria, Velthorst, Eva, Almansa, Jorge, Myin-Germeys, Inez, Shergill, Sukhi and Fett, Anne-Kathrin 2023. Do loneliness and social exclusion breed paranoia? An experience sampling investigation across the psychosis continuum. Schizophrenia Research: Cognition. 33, p. 100282. https://doi.org/10.1016/j.scog.2023.100282
Automatic detection of cognitive impairment with virtual reality
Mannan, Farzana A, Porffy, Lilla A, Joyce, Dan W, Shergill, Sukhwinder S and Celiktutan, O. 2023. Automatic detection of cognitive impairment with virtual reality. Sensors. 23 (2), p. 1026. https://doi.org/10.3390/s23021026
Neuroimaging oxytocin modulation of social reward learning in schizophrenia.
Mouchlianitis, Elias D, Tracy, D., Wigton, Rebekah, Vanes, Lucy D, Fett, A. and Shergill, Sukhi S 2022. Neuroimaging oxytocin modulation of social reward learning in schizophrenia. BJPsych Open. 8 (5), p. e175. https://doi.org/10.1192/bjo.2022.577
Cognitive bias modification for paranoia (CBM-pa): a randomised controlled feasibility study in patients with distressing paranoid beliefs.
Yiend, Jenny, Lam, C., Schmidt, Nora, Crane, Bryony, Heslin, Margaret, Kabir, Thomas, McGuire, Philip, Meek, Christopher, Mouchlianitis, Elias, Peters, Emmanuelle, Stahl, Daniel, Trotta, Antonella and Shergill, Sukhwinder 2022. Cognitive bias modification for paranoia (CBM-pa): a randomised controlled feasibility study in patients with distressing paranoid beliefs. Psychological Medicine. https://doi.org/10.1017/S0033291722001520
The importance of pro-social processing, and ameliorating dysfunction in schizophrenia. An FMRI study of oxytocin
Shergill, S., Rebekah Wigton, Derek K. Tracy, Tess M. Verneuil, Michaela Johns, Thomas White, Panayiota G. Michalopoulou, Bruno Averbeck and Sukhwinder Shergill 2022. The importance of pro-social processing, and ameliorating dysfunction in schizophrenia. An FMRI study of oxytocin. Schizophrenia Research: Cognition. 27. https://doi.org/10.1016/j.scog.2021.100221
Stimulating learning: A functional MRI and behavioral investigation of the effects of transcranial direct current stimulation on stochastic learning in schizophrenia
Natasza D. Orlov, Syed Ali Muqtadir, Hooman Oroojeni, Bruno Averbeck, John Rothwell and Sukhi S. Shergill 2022. Stimulating learning: A functional MRI and behavioral investigation of the effects of transcranial direct current stimulation on stochastic learning in schizophrenia. Psychiatry Research. 317, p. 114908. https://doi.org/10.1016/j.psychres.2022.114908
A novel virtual reality assessment of functional cognition: Validation study
Lilla Alexandra Porffy, Mitul A Mehta, Joel Patchit, Celia Boussebaa, Jack Brett, Teresa D’Oliveira, Elias Mouchlianitis and Sukhi Shergill. 2022. A novel virtual reality assessment of functional cognition: Validation study. Journal of Medical Internet Research. 24 (1), p. e27641. https://doi.org/10.2196/27641
VStore: Feasibility and acceptability of a novel virtual reality functional cognition task
Lilla A. Porffy, Mitul A. Mehta, Elias Mouchlianitis and Sukhi S. Shergill 2022. VStore: Feasibility and acceptability of a novel virtual reality functional cognition task. Frontiers in Virtual Reality.
Alpha3/alpha2 power ratios relate to performance on a virtual reality shopping task in ageing adults
Patchitt, Joel, Porffy, Lilla A., Whomersley, Gabriella, Szentgyorgyi, Timea, Brett, Jack, Mouchlianitis, Elias, Mehta, Mitul A., Nottage, Judith F. and Shergill, Sukhi S. 2022. Alpha3/alpha2 power ratios relate to performance on a virtual reality shopping task in ageing adults. Frontiers in Aging Neuroscience. 14, p. 876832. https://doi.org/10.3389/fnagi.2022.876832
The influence of trial-by-trial feedback on trust in health, first-episode and chronic psychosis
Lemmers-Jansen, I., Wichmann, Rune J., Perizonius, Sophie and Shergill, Sukhi S. 2022. The influence of trial-by-trial feedback on trust in health, first-episode and chronic psychosis. Games. 13 (5), p. e59. https://doi.org/10.3390/g13050059
Vortioxetine as adjunctive therapy in the treatment of schizophrenia
Redaelli, Sofia, Porffy, Lilla, Oloyede, Ebenezer, Dzahini, O., Lewis, Gabriella, Lobo, Maria, Whiskey, E. and Shergill, Sukhi S. 2022. Vortioxetine as adjunctive therapy in the treatment of schizophrenia. Therapeutic Advances in Psychopharmacology. 12, p. 204512532211100. https://doi.org/10.1177/20451253221110014
The role of cognitive control in the positive symptoms of psychosis
Horne, Charlotte M., Sahni, Angad, Pang, Sze W., Vanes, Lucy D., Szentgyorgyi, Timea, Averbeck, Bruno, Moran, Rosalyn J. and Shergill, Sukhwinder S. 2022. The role of cognitive control in the positive symptoms of psychosis. NeuroImage. Clinical. 34, p. 103004. https://doi.org/S2213-1582(22)00069-9
Direct eye gaze enhances the ventriloquism effect
Lavan, N., Chan, Wing Yue, Zhuang, Yongping, Mareschal, Isabelle and Shergill, Sukhwinder S. 2022. Direct eye gaze enhances the ventriloquism effect. Attention, Perception & Psychophysics. https://doi.org/10.3758/s13414-022-02468-5
Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations
Shergill, S., Amir Krivoy, Eromona Whiskey, Henrietta Webb-Wilson, Dan Joyce, Derek K. Tracy, Fiona Gaughran, James H. MacCabe and Sukhwinder S. Shergill 2021. Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations. Therapeutic Advances in Psychopharmacology. 11. https://doi.org/10.1177/20451253211037179
New approaches to antipsychotic medication adherence – safety, tolerability and acceptability
Taub, Sharon, Krivoy, Amir, Whiskey, Eromona and Shergill, Sukhi S. 2021. New approaches to antipsychotic medication adherence – safety, tolerability and acceptability. Expert Opinion on Drug Safety. 21 (4), pp. 517-524. https://doi.org/10.1080/14740338.2021.1983540
A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia
di Hou, Meng, Santoro, Viviana, Biondi, Andrea, Shergill, Sukhi S and Premoli, Isabella 2021. A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia. Journal of psychiatry & neuroscience : JPN. 46 (6), pp. E675-E701. https://doi.org/10.1503/jpn.210006